Stockscreener 앱 받기
11.01
2.42%
0.26
시간 외 거래:
11.01
전일 마감가:
$10.75
열려 있는:
$10.9
하루 거래량:
813.81K
Relative Volume:
1.06
시가총액:
$757.61M
수익:
$46.02M
순이익/손실:
$-70.80M
주가수익비율:
-6.0495
EPS:
-1.82
순현금흐름:
$-1.61M
1주 성능:
+4.06%
1개월 성능:
+6.27%
6개월 성능:
+74.48%
1년 성능:
+40.25%
1일 변동 폭
$10.74
$11.28
1주일 범위
$9.68
$11.28
52주 변동 폭
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
명칭
Eyepoint Pharmaceuticals Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
EYPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
11.01 | 708.23M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
EyePoint at H.C. Wainwright: Strategic Insights on Wet AMD Trials By Investing.com - Investing.com Canada
EyePoint (EYPT) Q2 Revenue Drops 44% - AOL.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript - MSN
JonesTrading Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $41 - 富途牛牛
EyePoint Completes Enrollment for Phase 3 Trials - MSN
Analysts Have Lowered Expectations For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Its Latest Results - 富途牛牛
EyePoint Pharmaceuticals Sees Analyst Expectations Lowered After Disappointing Q2 Results - AInvest
How did EYPT's revenue streams evolve in Q4 2024? - AInvest
Chardan Capital Reiterates "Buy" Rating for EyePoint Pharmaceuticals with $27 Price Target - AInvest
EyePoint signals 2026 LUGANO Phase III data and NDA filing for DURAVYU amid accelerated trial enrollment - MSN
Scotiabank Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
EyePoint Pharmaceuticals (EYPT): Chardan Capital Maintains "Buy" Rating | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2025 Earnings Call Transcript - Insider Monkey
EyePoint Pharmaceuticals Q2 2025 Earnings Preview: Revenue Expected at $6.63 Million - AInvest
EyePoint Pharmaceuticals Reports Q2 2025 Financial Results, Highlights Recent Developments and Milestones - AInvest
EyePoint Pharma Advances DURAVYU Trials Amid Financial Challenges - TipRanks
EyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating - TipRanks
EyePoint Pharmaceuticals: Promising Phase III Trials and Market Potential for Long-Acting TKI - TipRanks
EyePoint Pharmaceuticals (EYPT) Receives Updated Analyst Ratings | EYPT Stock News - GuruFocus
EyePoint: HC Wainwright raises PT to $23, maintains Buy rating - AInvest
EyePoint reports Q2 EPS (85c), consensus (80c) - TipRanks
Earnings call transcript: Eyepoint Pharmaceuticals Q2 2025 sees revenue miss, stock drops - Investing.com India
EyePoint Pharmaceuticals Drops 10.38% on Q2 Loss, Clinical Progress - AInvest
EyePoint Pharmaceuticals Reports Q2 Loss, Misses Revenue Estimates - AInvest
EyePoint Pharmaceuticals Inc Reports Q2 2025 Earnings: EPS of ($ - GuruFocus
EyePoint Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmol - GuruFocus
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewswire
EyePoint Q2 revenue falls 44%, net loss widens - MarketScreener
EyePoint Pharmaceuticals CEO to Participate in H.C. Wainwright Ophthalmology Conference. - AInvest
EyePoint Pharmaceuticals CEO Reveals Latest Retinal Disease Breakthroughs at Major Ophthalmology Conference - Stock Titan
EyePoint Reports Second Quarter 2025 Financial Results and Highl - GuruFocus
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals
EyePoint's DURAVYU Phase 3 Trials Break Enrollment Records: 800+ Wet AMD Patients in Just 7 Months - Stock Titan
EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Prev - GuruFocus
EyePoint Pharmaceuticals Inc expected to post a loss of 80 cents a shareEarnings Preview - TradingView
What drives EyePoint Pharmaceuticals Inc. stock priceTake advantage of unprecedented market momentum - Jammu Links News
What makes EyePoint Pharmaceuticals Inc. stock price move sharplyMaximize portfolio growth with strategic plans - Jammu Links News
What is EyePoint Pharmaceuticals Inc. company’s growth strategyPhenomenal trading returns - Jammu Links News
Does EyePoint Pharmaceuticals Inc. stock perform well during market downturnsMaximize returns with strategic trading plans - Jammu Links News
Should I hold or sell EyePoint Pharmaceuticals Inc. stock in 2025Achieve breakthrough growth with proven strategies - Jammu Links News
Why is EyePoint Pharmaceuticals Inc. stock attracting strong analyst attentionBreakout profit opportunities - Jammu Links News
How volatile is EyePoint Pharmaceuticals Inc. stock compared to the marketFree Stock Market Forecast Reports - Jammu Links News
What catalysts could drive EyePoint Pharmaceuticals Inc. stock higher in 2025Navigate market shifts with confidence - Jammu Links News
Is EyePoint Pharmaceuticals Inc. stock overvalued or undervaluedMassive portfolio appreciation - Jammu Links News
What are EyePoint Pharmaceuticals Inc. company’s key revenue driversAccelerated wealth expansion - Jammu Links News
Is it the right time to buy EyePoint Pharmaceuticals Inc. stockFree Investment Community - Jammu Links News
What analysts say about EyePoint Pharmaceuticals Inc. stockAchieve breakthrough investment performance - Jammu Links News
How many analysts rate EyePoint Pharmaceuticals Inc. as a “Buy”Rapid wealth creation - Jammu Links News
Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD - MSN
Eyepoint Pharmaceuticals Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.67%
자본화:
|
볼륨(24시간):